Ask AI
CDK46i Adherence mBC

CE

Improving Adherence to Oral CDK4/6 Inhibitors in HR+/HER2- mBC

Pharmacists: 0.25 contact hour (0.025 CEUs)

Released: December 31, 2025

Expiration: June 30, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 58-year-old woman with hormone receptor (HR)–positive/HER2-negative metastatic breast cancer is prescribed ribociclib on a 21-day-on, 7-day-off schedule. She reports taking the medication correctly during the first 21 days but forgot to restart therapy after the planned 7-day break. She has not experienced any adverse events (AEs) on therapy and wishes to continue treatment. Which intervention is most appropriate to improve adherence for this patient?

2.

A 62-year-old woman with HR-positive/HER2-negative metastatic breast cancer is receiving a CDK4/6 inhibitor in combination with endocrine therapy. She reports fatigue and mild nausea and admits that, “on bad days,” she skips doses of her CDK4/6 inhibitor without informing her care team. What is the best next step to support adherence?